Passage Bio, Inc. (NASDAQ:PASG) has seen 650,172 shares traded in the last trading session. The company, currently valued at $1.29 Billion, closed the last trade at $28.41 per share which meant it lost -$6.65 on the day or -18.97% during that session. The PASG stock price is -34.57% off its 52-week high price of $38.23 and 71.52% above the 52-week low of $8.09. If we look at the company’s 10-day average daily trading volume, we find that it stood at 591.71 Million shares traded. The 3-month trading volume is 198.43 Million shares.
The consensus among analysts is that Passage Bio, Inc. (PASG) is an Overweight stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 4 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.57.
Passage Bio, Inc. (NASDAQ:PASG) trade information
Wall Street analysts have a consensus price target for the stock at $28.5, which means that the shares’ value could jump 0.32% from current levels. The projected low price target is $25 while the price target rests at a high of $32.5. In that case, then, we find that the current price level is +14.4% off the targeted high while a plunge would see the stock lose -12% from current levels.
Passage Bio, Inc. (PASG) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +0% over the past 5 years. Earnings growth for 2020 is a modest +0% while over the next 5 years, the company’s earnings are expected to increase by 0%.
Passage Bio, Inc. (NASDAQ:PASG)’s Major holders
Insiders own 19.27% of the company shares, while shares held by institutions stand at 56.12% with a share float percentage of 69.51%. Investors are also buoyed by the number of investors in a company, with Passage Bio, Inc. having a total of 21 institutions that hold shares in the company. The top two institutional holders are Orbimed Advisors LLC. with over 6.96 Million shares worth more than $109.67 Million. As of March 30, 2020, Orbimed Advisors LLC. held 15.35% of shares outstanding.
The other major institutional holder is Frazier Management LLC, with the holding of over 5.01 Million shares as of March 30, 2020. The firm’s total holdings are worth over $78.9 Million and represent 11.05% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Select Portfolios – Biotechnology and Fidelity Advisor Biotechnology Fund. As of March 30, 2020, the former fund manager holds about 1.33% shares in the company for having 602467 shares of worth $9.49 Million while later fund manager owns 438.46 Thousand shares of worth $6.91 Million as of March 30, 2020, which makes it owner of about 0.97% of company’s outstanding stock.